HLJ1 is an endogenous Src inhibitor suppressing cancer progression through dual mechanisms.
| Image |  |
|---|---|
| Description | scientific article published on 11 April 2016 |
| Author/s |
author: Sung-Liang Yu Kang-Yi Su |
| Publication date | April 11, 2016 |
| Language | English |
| Country of origin | |
| Wikipedia link | |
| Copyright status | |
| Missing/wrong data? | Edit Wikidata item |